Recent News for OPTN - OptiNose, Inc.

Date Title
Oct 4 Optinose Appoints Michael Richardson to New Position of Vice President, Business Development
Sep 27 Optinose to Present at the 2019 Cantor Global Healthcare Conference
Sep 26 Currax™ Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®
Sep 26 OptiNose out-licenses Onzetra Xsail to Currax Pharma
Sep 26 OptiNose Announces License Agreement Related to ONZETRA XSAIL
Sep 17 Optinose commercial chief bids adieu
Sep 17 Optinose Announces Departure of Chief Commercial Officer
Sep 12 OptiNose secures $150M in new debt capital
Sep 12 Optinose Announces $150 Million Debt Financing from Pharmakon
Sep 11 Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way?
Sep 3 65 Biggest Movers From Friday
Aug 30 RRD, PBYI, KBR and TLRD among notable after hours movers
Aug 13 OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says
Aug 13 Microcaps mostly among midday movers
Aug 13 OptiNose, Inc. 2019 Q2 - Results - Earnings Call Slides
Aug 13 Deciphera Pharmaceuticals leads healthcare gainers; Plus Therapeutics among the losers
Aug 13 Optinose up 14% after Q2 beat
Aug 13 The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
Aug 13 OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript
Aug 12 OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2019 Results - Earnings Call Transcript
Aug 12 OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
Aug 12 OptiNose EPS beats by $0.08, beats on revenue
Aug 12 Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
Aug 12 OptiNose, Inc. to Host Earnings Call
Aug 11 The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Back to the Main OPTN Page...